KUALA LUMPUR: Perak-based Hovid Bhd has received the manufacturing licence for its Ipoh plant from the National Pharmaceutical Control Bureau.
The healthcare and pharmaceutical company said on Monday it had just received the licence for the Ipoh plant along Jalan Tunku Abdul Rahman from the bureau, which is under the Ministry of Health.
“The licence is valid from May 5, 2017, to be renewed three months prior to the expiry date on Dec 31, 2017,” it said, enabling it to resume full operations.
Recall, the Health Ministry in January this year had repealed the manufacturing licences of both of Hovid’s facilities in Perak.
The revocation order came following an audit by the National Pharmaceutical Regulatory Agency (NPRA) on Hovid’s facilities, which found that the latter’s Good Manufacturing Practice (GMP) compliance was not acceptable and its pharmaceutical quality system did not comply with the latest cGMP requirements.
The re-issuance of the licences would be subject to the NPRA being satisfied with the outcome of its audit.
In March, Hovid said it had received the manufacturing licence for its Chemor plant, valid from March 6, 2017. It has to be renewed three months prior to the expiry date on Dec 31, 2017.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
